Clinical Trials Browser

Recurrence, Leukemia, Myeloid, Acute

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1 Recruiting

18 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

3 enrolled

Gynecologic

Fallopian Tube Neoplasms, Recurrence

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Neoplasm Metastasis, Recurrence

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT05895370 2023-06-08

GI-HPVT-01

Phase 1 Unknown

12 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03213964 2021-03-12

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Phase 1 Completed

10 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Recurrence

NCT01517347 2016-10-24

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Phase NA Terminated

90 enrolled

Other hematologic neoplasm

Leukemia, Recurrence

NCT01081808 2015-03-25

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

Phase 1 Terminated

2 enrolled

Carcinoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence

Clinical Trials

NK4AML

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Immunotherapy for the Treatment of Advanced Solid Tumor

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

GI-HPVT-01

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors